Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience

Abstract Since 2016, a next-generation sequencing (NGS) panel targeting 68 genes frequently mutated in lymphoid malignancies is an accredited part of routine diagnostics at the Institute of Pathology in Basel, Switzerland. Here, we retrospectively evaluate the feasibility and utility of integrating this NGS platform into routine practice on 80 diagnostic cases of lymphoid proliferations. NGS analysis was useful in most instances, yielding a diagnostically, predictively and/or prognostically meaningful result. In 35 out of the 50 cases, in which conventional histopathological evaluation remained indecisive, molecular subtyping with the NGS panel was helpful to either confirm or support the favored diagnosis, enable a differential diagnosis, or seriously question a suspected diagnosis. A total of 61 actionable or potentially actionable mutations in 34 out of 80 cases that might have enabled patient selection for targeted therapies was detected. NGS panel analysis had implications for prognosis in all 15 cases interrogated for risk assessment.

[1]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[2]  L. Bubendorf,et al.  Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon , 2019, Acta Cytologica.

[3]  K. Davies,et al.  Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing. , 2019, Journal of Visualized Experiments.

[4]  A. Intlekofer,et al.  Using genomic data for selecting the treatment of lymphoma patients. , 2019, Current opinion in hematology.

[5]  A. Tzankov,et al.  T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights , 2018, Leukemia & lymphoma.

[6]  P. Tamayo,et al.  Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials , 2018, Cancers.

[7]  J. Delabie,et al.  Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease , 2018, British journal of haematology.

[8]  A. Cleton-Jansen,et al.  Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing. , 2018, The Journal of molecular diagnostics : JMD.

[9]  A. Tzankov,et al.  Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines , 2018, Leukemia & lymphoma.

[10]  Alexander V Penson,et al.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.

[11]  F. Cavalli,et al.  Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. , 2018, Blood.

[12]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[13]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[14]  A. Tzankov,et al.  High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations , 2018, Leukemia.

[15]  T. Haferlach,et al.  Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing , 2018, Leukemia.

[16]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[17]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[18]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[19]  J. Hernández-Rivas,et al.  Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia , 2017, British Journal of Cancer.

[20]  Ryan D. Morin,et al.  Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. , 2017, Blood.

[21]  K. Naresh,et al.  Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders , 2017, British journal of haematology.

[22]  R. Foà,et al.  Diffuse large B-cell lymphoma genotyping on the liquid biopsy. , 2017, Blood.

[23]  C. Mamot,et al.  Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort , 2017, Journal of Hematology & Oncology.

[24]  H. Kantarjian,et al.  Cancer Drugs: An International Comparison of Postlicensing Price Inflation. , 2017, Journal of oncology practice.

[25]  O. Elemento,et al.  CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. , 2017, Cancer discovery.

[26]  J. Delabie,et al.  High Frequency of Somatic Mutations of KMT2D and CARD11 Genes in Cold Agglutinin Disease , 2016 .

[27]  R. Kirken,et al.  Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. , 2016, Clinical cancer drugs.

[28]  R. Yelensky,et al.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.

[29]  C. Ruiz,et al.  Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis , 2016, Leukemia.

[30]  S. Lippman,et al.  Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience , 2016, Molecular Cancer Therapeutics.

[31]  C. Copie-Bergman,et al.  Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study , 2016, Clinical Cancer Research.

[32]  Ryan D. Morin,et al.  Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.

[33]  Donavan T. Cheng,et al.  Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. , 2015, Drug discovery today.

[34]  M. Grever,et al.  Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. , 2015, The New England journal of medicine.

[35]  L. Staudt,et al.  Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling , 2015, The American journal of surgical pathology.

[36]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[37]  E. V. Van Allen,et al.  Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.

[38]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[40]  N. Leslie,et al.  PTEN inhibitors: an evaluation of current compounds. , 2015, Advances in biological regulation.

[41]  J. Lee,et al.  Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. , 2014, Cancer research.

[42]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[43]  A. Behrens,et al.  ATM signalling and cancer , 2014, Oncogene.

[44]  A. Marx,et al.  Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall , 2014, Virchows Archiv.

[45]  S. Lippman,et al.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.

[46]  H. Goldschmidt,et al.  Targeting the BRAF V600E mutation in multiple myeloma. , 2013, Cancer discovery.

[47]  R. Kurzrock,et al.  Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Richard Simon,et al.  Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.

[49]  R. Spang,et al.  SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients , 2012, Oncotarget.

[50]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[51]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[52]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[53]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[54]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[55]  C. Bloomfield,et al.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia , 2012, Leukemia.

[56]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[57]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[58]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[59]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[60]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[61]  J. Renauld,et al.  Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors , 2011, Haematologica.

[62]  C. Klemke,et al.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.

[63]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[64]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[65]  Lee T. Sam,et al.  Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.

[66]  M. Muckenthaler,et al.  Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.

[67]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.